Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047347 | 0.95 | ACHE (0.36) | CHRM5ADRA2CACHENCF1CCR2 | |
| SCHEMBL24319652 | 0.91 | ALDH1A1 (0.39) | CHRM5ADRA2CACHECCR2KCNH2 | |
| SCHEMBL26705153 | 0.91 | NCF1 (0.43) | CHRM5ADRA2CACHENCF1CCR2 | |
| SCHEMBL12403098 | 0.90 | CHRM5 (0.46) | CHRM5ADRA2CACHENCF1CCR2 | |
| SCHEMBL12434924 | 0.90 | CHRM5 (0.52) | CHRM5ADRA2CACHENCF1CCR2 | |
| SCHEMBL25571696 | 0.89 | NCF1 (0.46) | CHRM5ADRA2CACHENCF1CCR2 | |
| SCHEMBL24745088 | 0.89 | DRD2 (0.37) | CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL19590887 | 0.87 | CHRM5 (0.56) | CHRM5ADRA2CACHECYP1A2 | |
| SCHEMBL24480239 | 0.87 | ACHE (0.44) | CHRM5ADRA2CACHENCF1KCNH2 | |
| SCHEMBL26705143 | 0.87 | KDM4E (0.33) | CHRM5ADRA2CACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348427-A1 | COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | CHRM5 2288/4885ADRA2C 134/4885ACHE 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.